Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices

This article was originally published in The Gray Sheet

Executive Summary

Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.

You may also be interested in...



Eight Products Enter US FDA’s Opioid Challenge

After spending the past six months receiving and reviewing hundreds of product applications, US FDA has decided to select eight promising devices and diagnostics to help tackle the opioid crisis.

FDA’s Expedited PMA Pathway Proposal: To Expand Or Contain?

Companies want FDA to expand the bounds of its accelerated device development program, while others urge FDA to be cautious.

Leap Ahead With EAP? FDA Proposes New Expedited PMA Pathway

The newly proposed “expedited access” PMA program combines early and outsized interactions between reviewers and manufacturers with the promise of lightened premarket requirements for selected products – if the potential pay off to patients is large enough and postmarket controls are sufficient.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT031129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel